Retagliptin is a DPP-4 inhibitor for type 2 diabetes mellitus research
**Background** Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and the progressive failure of pancreatic beta cells to secrete sufficient insulin. A key component…